RecruitMe Clinical Trial

DETERMINING CHANGE IN CARDIOVASCULAR AND METABOLIC RISKS IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING BCR-ABL TYROSINE KINASE INHIBITOR FIRST-LINE THERAPY IN THE UNITED STATES
Determining Changing in Cardiovascular and Metabolic Risks in Patients with Chronic Myeloid Leukemia
Sponsor:Bristol-Myers Squibb
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR8507
U.S. Government ID:NCT03045120
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This study will see how the treatment you will receive for your chronic myeloid leukemia affects cardiovascular and metabolic risk factors. The treatments that are being studied are called BCR-ABL1 tyrosine kinase inhibitors (TKIs) (i.e., dasatinib, imatinib, nilotinib). Subjects who are eligible for the study will be starting treatment for chronic myeloid leukemia for the first time. Approximately 200 patients are expected to participate in this study in the United States across 25 community and academicbased sites.

Do You Qualify?
Are you 18 years of age or older?YesNo
Have you been diagnosed with chronic myeloid leukemia?YesNo
Have you received prior treatment for CML?YesNo
Submit
Cancel
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162